are idh mutations good minimal residual disease (mrd) markers in acute myeloid leukemia (aml)?
Published 7 years ago • 470 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
2:08
the impact of idh mutations on the outcomes of patients with aml & inhibitors under investigation
-
12:59
acute leukemias: is mrd already a surrogate for survival?
-
1:14
the impact of idh mutations in mds & evaluating the role of idh inhibitors
-
1:23
the value of mrd as a marker for disease eradication in aml
-
1:56
the efficacy of olutasidenib in patients with r/r idh-mutant aml
-
25:18
what are common specifications within mdr & ivdr? [stefan bolleininger]
-
4:10
explore idh mutations
-
5:13
a microbial signature for crohn's disease
-
2:53
the prognostic impact of idh mutations and the role of idh inhibitors in mds
-
1:53
treatment strategies for patients with idh1/2-mutated aml ineligible for intensive chemotherapy
-
1:15
outcomes of non-intensive chemotherapy differ for idh1 and idh2-mutated aml
-
1:57
mrd negativity in all
-
2:22
next-generation methodologies: the future for mrd monitoring in all?
-
0:56
promising combinations being explored for idh1 & idh2-mutated aml
-
2:17
the benefit of detecting minimal residual disease in mm
-
1:17
the curative potential of allosct in the treatment of hr-mds
-
1:32
idiome: ivosidenib in idh1 mutant mds
-
3:35
the potential of mrd as a surrogate marker in randomized trials to accelerate drug approvals
-
3:48
mrd-driven hsct for all
-
2:02
unmet needs in high-risk mds and future therapeutic strategies
-
2:17
opinion: value of mrd as an endpoint in hem-onc clinical trials
-
1:10
should we adapt treatment based on mrd status in mm?